Abby AlpertGong, Hoyt2023-05-232023-05-232018-01-012018-09-11https://repository.upenn.edu/handle/20.500.14332/47418Global Health Technology Assessment (HTA) bodies vary in their scope and approach in Cost Effective Analyses (CEA) evaluating the clinical and economic efficacy of a proposed therapeutic against established metrics. This study characterized specific CEA approaches of various countries across standardized development indices and tested conditions of regression correlation against respective country health outcomes of interest. Additionally, we validate the existence of implicit and explicit values in country willingness-to-pay (WTP) thresholds and its statistically significance with country health expenditure and quality of care. Our multivariate regression models show that while CEA characteristics vary across countries, ultimate health outcomes are not dictated by CEA approach factors but rather in the broader context of country GDPPC development.Comparative Effectiveness ResearchPharmacoeconomicsHealth Technology Assessmentcost-effective analysisoutcomes researchBusinessEconometricsHealth EconomicsWorking Paper